Shots:

• Biocytogen to receive an up front & will be eligible to receive an option-exercise fee, development & commercial milestones along with royalties upon exercise of each option
• ADC will obtain the license from Biocytogen to evaluate mAb/or biparatopic Abs against 3 tumor targets developed through Biocytogen’s Project Integrum (RenMice HiTS Platform) & also get the option to license selected Abs for development & commercialization globally along with responsibility for the feasibility studies if the option is exercised. Biocytogen reserves all global rights for these Abs
• The agreement will combine Biocytogen’s strength in Ab development with ADC’s expertise, and track record in payload and linker technology to develop novel ADC therapies

Ref: Businesswire| Image: Biocytogen